Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment
Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas
Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies
Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma
Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes following transplantation
MS-553 shows promise in treating chronic lymphocytic leukaemia